Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222444 | 1.00 | MCHR1 (0.41) | MCHR1TSHRMAOAMAOBACHE | |
| SCHEMBL4229585 | 0.96 | MAOA (0.38) | MCHR1TSHRMAOAMAOBACHE | |
| SCHEMBL4229579 | 0.96 | MAOA (0.38) | MCHR1TSHRMAOAMAOBACHE | |
| SCHEMBL4226356 | 0.94 | MCHR1 (0.47) | MCHR1ACHEHDAC1EHMT1HDAC6 | |
| SCHEMBL4226363 | 0.94 | MCHR1 (0.47) | MCHR1ACHEHDAC1EHMT1HDAC6 | |
| SCHEMBL4218821 | 0.93 | ACHE (0.43) | MCHR1MAOAMAOBACHEHDAC1 | |
| SCHEMBL4218810 | 0.93 | ACHE (0.43) | MCHR1MAOAMAOBACHEHDAC1 | |
| SCHEMBL4223490 | 0.93 | MCHR1 (0.41) | MCHR1MAOAMAOBACHEHDAC1 | |
| SCHEMBL4223498 | 0.93 | MCHR1 (0.41) | MCHR1MAOAMAOBACHEHDAC1 | |
| SCHEMBL4231670 | 0.92 | HTR2A (0.45) | MAOAMAOBACHEHDAC1EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | MCHR1 997/4885TSHR 601/4885MAOA 823/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | MCHR1 1149/4885TSHR 536/4885MAOA 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.